REAL-WORLD STUDY: PURAPLY® AM SUPPORTED HEALING IN LARGE, DIFFICULT-TO-HEAL WOUNDS
The first prospective, large (N=307), multi-center (28 sites) cohort study of PuraPly® AM, used as an antimicrobial barrier, showed that 86% of all PuraPly® AM-treated wounds demonstrated improvement in the wound bed condition.3
TAKE CONTROL BEFORE
BIOFILM RE-FORMS.
USE PURAPLY® AM
& PURAPLY® XT.
PuraPly® AM and PuraPly® XT provide sustained antimicrobial effectiveness within the product to help prevent biofilm reformation.4,5
WHY PURAPLY® AM & PURAPLY® XT>
confirmation of control: the
puraply® portfolio is backed by
an expanding evidence base
Examine the scientific and real-world studies that demonstrate the effectiveness of PuraPly® AM and PuraPly® XT, when used as antimicrobial barriers.
EFFECTIVENESS STUDYDavis SC, et al. Int Wound J. 2022;19(1):
86-99.
9(10):691-703.
IN DIFFICULT-TO-HEALOropallo AR. Plast Reconstr Surg
Glob Open. 2019; 7:e2047.
Organogenesis' Circle of Care is a program providing information and resources to customers. The program’s resources include information about:
View all Services>Please refer to the PuraPly AM Instructions for Use and
PuraPly XT Instructions for Use for complete prescribing information.
1. PuraPly Antimicrobial [package insert]. Canton, MA: Organogenesis Inc; 2023. 2. PuraPly XT [package insert]. Canton, MA: Organogenesis Inc; 2023. 3. Bain MA, et al. J Comp Eff Res. 2020;9(10):691-703. 4. Davis SC, et al. Int Wound J. 2022;19(1):86-99. 5. Brantley J, et al. Wounds Int. 2016;7(3):1-5.